NASDAQ:ZLAB Zai Lab - ZLAB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. $44.88 +0.41 (+0.92%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$43.70▼$45.0950-Day Range$28.97▼$48.1052-Week Range$20.98▼$61.29Volume562,619 shsAverage Volume996,863 shsMarket Capitalization$4.39 billionP/E RatioN/ADividend YieldN/APrice Target$97.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Zai Lab MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside117.2% Upside$97.50 Price TargetShort InterestHealthy2.78% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.41Based on 3 Articles This WeekInsider TradingSelling Shares$74,160 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.08) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector484th out of 1,055 stocksPharmaceutical Preparations Industry235th out of 519 stocks 3.5 Analyst's Opinion Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $97.50, Zai Lab has a forecasted upside of 117.2% from its current price of $44.88.Amount of Analyst CoverageZai Lab has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.78% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zai Lab has recently increased by 1.12%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ZLAB. Previous Next 3.0 News and Social Media Coverage News SentimentZai Lab has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zai Lab this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $74,160.00 in company stock.Percentage Held by InsidersOnly 6.26% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions59.46% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($5.08) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Zai Lab (NASDAQ:ZLAB) StockZai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.Read More Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLAB Stock News HeadlinesJanuary 27, 2023 | finance.yahoo.comBiotech Stocks Reward Shareholders Who Handle The Bumpy RideJanuary 18, 2023 | technews.tmcnet.comZai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China's National Reimbursement Drug ListJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 18, 2023 | msn.comParatek/ Zai Lab antibiotic added for reimbursement in ChinaJanuary 18, 2023 | finance.yahoo.comZai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug ListJanuary 9, 2023 | benzinga.comZai Lab Appoints Michel Vounatsos To Its Board of DirectorsJanuary 9, 2023 | finance.yahoo.comZai Lab Appoints Michel Vounatsos To Its Board of DirectorsJanuary 5, 2023 | seekingalpha.comHot Stocks: SI plunges on restructuring; BBBY sets new 52-week low; NVCR, ZLAB skyrocket; LW earningsJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 5, 2023 | finanznachrichten.deZai Lab Limited: Zai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival EndpointJanuary 5, 2023 | markets.businessinsider.comZai Lab And Novocure Announce LUNAR Study Meets Primary EndpointJanuary 5, 2023 | realmoney.thestreet.comNovoCure Gaps Sharply Higher for a Breakout: How to Play ItJanuary 5, 2023 | msn.comNovocure, Zai Lab surge as lung cancer therapy meets main goal in late-stage trialJanuary 5, 2023 | finance.yahoo.comNovocure, Zai shares rally after lung-cancer treatment meets primary endpoint in studyJanuary 5, 2023 | finance.yahoo.comThis Good News on Cancer Sent 2 Nasdaq Stocks SoaringJanuary 5, 2023 | finance.yahoo.comNovocure Stock Surges As Tumor Treating Fields Shows Overall Survival In Lung Cancer PatientsJanuary 5, 2023 | finance.yahoo.comZai Lab and Novocure Announce Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival EndpointJanuary 4, 2023 | msn.comWhat's Going On With Zai Lab StockJanuary 3, 2023 | finance.yahoo.comZai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and DevelopmentJanuary 1, 2023 | finance.yahoo.comCompanies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In GrowthDecember 20, 2022 | finance.yahoo.comZai Lab Announces Participation in January Investor ConferencesDecember 15, 2022 | finance.yahoo.comZai Lab Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual PlenaryDecember 5, 2022 | finance.yahoo.comZai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)November 12, 2022 | finance.yahoo.comZai Lab Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 11, 2022 | finance.yahoo.comZai Lab Announces Third Quarter 2022 Financial Results and Corporate UpdatesNovember 10, 2022 | seekingalpha.comZai Lab Limited (ZLAB) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comZai Lab Announces Third Quarter 2022 Financial Results and Corporate UpdatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLAB Company Calendar Last Earnings11/09/2022Today1/28/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees1,951Year FoundedN/APrice Target and Rating Average Stock Price Forecast$97.50 High Stock Price Forecast$127.00 Low Stock Price Forecast$79.00 Forecasted Upside/Downside+117.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($6.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-704,470,000.00 Net Margins-301.79% Pretax Margin-301.41% Return on Equity-47.41% Return on Assets-40.72% Debt Debt-to-Equity RatioN/A Current Ratio7.78 Quick Ratio7.59 Sales & Book Value Annual Sales$144.31 million Price / Sales30.45 Cash FlowN/A Price / Cash FlowN/A Book Value$14.31 per share Price / Book3.14Miscellaneous Outstanding Shares97,910,000Free Float91,780,000Market Cap$4.39 billion OptionableOptionable Beta1.18 Key ExecutivesDr. Ying Du Ph.D. (Age 57)Founder, Chairperson & CEO Comp: $1.64MMr. Ki Chul Cho (Age 45)Chief Financial Officer Comp: $720.97kMr. Frazor Titus Edmondson III (Age 57)Chief Legal Officer & Corp. Sec. Comp: $829kDr. Harald Reinhart M.D. (Age 71)Pres and Head of Global Devel. for Neuroscience, Autoimmune & Infectious Diseases Comp: $845.94kMr. Joshua L. Smiley (Age 53)Chief Operating Officer Dr. Peter Huang Ph.D.Chief Scientific OfficerMs. Ann E. Beasley J.D.Chief Compliance OfficerDr. Ning Xu M.D. (Age 58)Exec. VP & Head of Clinical Operations Dr. Jonathan J. Wang M.B.A. (Age 41)MBA, Ph.D., Chief Bus. Officer Dr. James Yan DABT (Age 59)M.D., Ph.D., Chief Operating Officer of R&D More ExecutivesKey CompetitorsCytokineticsNASDAQ:CYTKIntra-Cellular TherapiesNASDAQ:ITCIAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsM&G Investment Management Ltd.Bought 49,001 shares on 1/27/2023Ownership: 0.465%National Bank of Canada FIBought 38,400 shares on 1/24/2023Ownership: 0.039%Genesis Investment Management LLPBought 72,639 shares on 1/20/2023Ownership: 1.522%WealthPlan Investment Management LLCBought 39,393 shares on 12/12/2022Ownership: 0.040%Bank of New York Mellon CorpBought 6,367 shares on 12/8/2022Ownership: 0.091%View All Insider TransactionsView All Institutional Transactions ZLAB Stock - Frequently Asked Questions Should I buy or sell Zai Lab stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ZLAB shares. View ZLAB analyst ratings or view top-rated stocks. What is Zai Lab's stock price forecast for 2023? 3 Wall Street analysts have issued 1 year price objectives for Zai Lab's stock. Their ZLAB share price forecasts range from $79.00 to $127.00. On average, they predict the company's share price to reach $97.50 in the next twelve months. This suggests a possible upside of 117.2% from the stock's current price. View analysts price targets for ZLAB or view top-rated stocks among Wall Street analysts. How have ZLAB shares performed in 2023? Zai Lab's stock was trading at $30.70 at the beginning of the year. Since then, ZLAB stock has increased by 46.2% and is now trading at $44.88. View the best growth stocks for 2023 here. When is Zai Lab's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our ZLAB earnings forecast. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) issued its earnings results on Wednesday, November, 9th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by $0.48. The company earned $57.54 million during the quarter, compared to analyst estimates of $53.58 million. Zai Lab had a negative trailing twelve-month return on equity of 47.41% and a negative net margin of 301.79%. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), Niu Technologies (NIU), JD.com (JD), Bilibili (BILI), Marvell Technology (MRVL), Baidu (BIDU), BioXcel Therapeutics (BTAI) and Baozun (BZUN). When did Zai Lab IPO? (ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. What is Zai Lab's stock symbol? Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB." Who are Zai Lab's major shareholders? Zai Lab's stock is owned by a variety of institutional and retail investors. Top institutional investors include Genesis Investment Management LLP (1.52%), M&G Investment Management Ltd. (0.47%) and National Bank of Canada FI (0.04%). Insiders that own company stock include Harald Reinhart, John D Diekman, John D Diekman, Kai-Xian Chen, Peter Wirth, Tao Fu, William Ki Chul Cho, William Lis and Ying Du. View institutional ownership trends. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Zai Lab's stock price today? One share of ZLAB stock can currently be purchased for approximately $44.88. How much money does Zai Lab make? Zai Lab (NASDAQ:ZLAB) has a market capitalization of $4.39 billion and generates $144.31 million in revenue each year. The company earns $-704,470,000.00 in net income (profit) each year or ($6.22) on an earnings per share basis. How many employees does Zai Lab have? The company employs 1,951 workers across the globe. How can I contact Zai Lab? Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The official website for the company is www.zailaboratory.com. The company can be reached via phone at 862161632588, via email at jsteier@burnsmc.com, or via fax at 86-21-6163-2570. This page (NASDAQ:ZLAB) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.